Table 3.
Anticancer NRPs from marine microbes.
| Sr. No. | NRPs | Chemical architecture | Source | Biological target | Biological active value (MIC/IC50/GI50/ID50/ED50) | References |
|---|---|---|---|---|---|---|
| BACTERIA | ||||||
| 1. | Mixirins A–C (60–62) | Cyclopeptide | Bacillus sp. | HCT-116 cells (colon) | 0.68, 1.6, 1.3 μg/ml | Zhang et al., 2004 |
| 2. | Mechercharmycin A (63) Mechercharmycin B (64) | Cyclic peptide | Thermoactinomyces sp. | A549 cells (lung), Jurkat cells | 4.0 × 10−8 M 4.6 × 10−8 M | Kanoh et al., 2005 |
| 3. | Bromoalterochromide A (65) and A' (66) | Chromo peptide | Pseudoalteromonas maricaloris | Strongylocentrotus intermedius eggs | – | Speitling et al., 2007 |
| 4. | Lucentamycins A–D (67–70) | – | Nocardiopsis lucentensis | HCT-116 cells (colon) | 0.20 and 11 μM | Cho et al., 2007 |
| 5. | Piperazimycins A–C (71–73) | Cyclic hexadepsipeptide | Streptomyces sp. | HCT-116 cells (colon) | 76 ng/mL | Miller et al., 2007 |
| 6. | Urukthapelstatin A (74) | Cyclic thiopeptide | Mechercharimyces asporophorigenens | A549 cells (lung) | 12 nM | Matsuo et al., 2007 |
| 7. | Arenamides A–C (75–77) | Cyclo hexadepsipeptide | Salinispora arenicola | Tumor necrosis factor | 3.7 and 1.7 μM | Asolkar et al., 2008 |
| 8. | Bacillistatins 1-2 (78–79) | Cyclodepsipeptide | Bacillus silvestris | P388 (murine lymphocytic leukemia); BXPC-3 (pancreas); MCF-7 (breast); SF-268 (CNS); NCI- H460 (lung); KM20L2 (colon); DU- 145 (prostate) | 10−4−10−5 μg/mL | Pettit et al., 2009 |
| 9. | Turnagainolides A–B (80–81) | Cyclic peptide | Bacillus sp. | PI3K pathway | – | Li et al., 2011 |
| 10. | Padanamides A–B (82–83) | Linear tetrapeptide | Streptomyces sp. | Jurkat cells | 20 μg/mL | Williams et al., 2011 |
| 11. | Ohmyungsamycins A–B (84–85) | Cyclic peptide | Streptomyces sp. | Cytotoxic | 359–816 nM and 12.4–16.8 μM | Um et al., 2013 |
| 12. | Proximicin A–C (86–88) | – | Verrucosispora strain MG-37 | AGS (gastric), HepG2 (hepatocellular), MCF 7 (breast) | 0.6, 1.5, 0.25 μg/mL 0.8, 9.5, 0.7 μg/mL 7.2, 5.0, 9.0 μg/mL | Fiedler et al., 2008 |
| CYANOBACTERIA | ||||||
| 13. | Hoiamide A (89) | Cyclic depsipeptide | An assemblage of L. majuscula and Phormidium gracile | Voltage-gated sodium channel | 92.8 nM | Pereira et al., 2009 |
| 14. | Yanucamides A–B (90–91) | Cyclic depsipeptide | Lyngbya majuscule and Schizothrix sp. | Brine shrimp toxicity | 5 ppm | Sitachitta et al., 2000 |
| 15. | Lyngbyabellins A (92) | Cyclic depsipeptide | L. majuscula | KB cells LoVo cells | 0.03 and 0.50 μg/mL | Luesch et al., 2000 |
| 16. | Lyngbyabellin B (93) | Cyclic depsipeptide | L. majuscula | Brine shrimp (Artemia salina) | 3.0 ppm | Milligan et al., 2000 |
| 17. | Microcyclamide (94) | Cyclic hexapeptide | Microcystis aeruginosa | P388 murine leukemia cells | 24–30 μg/mL | Ishida et al., 2000 |
| 18. | Apratoxin A (95) | – | L. majuscula | KB cells and LoVo cancer cells | 0.52 nM 0.36 nM | Luesch et al., 2001b |
| 19. | Pitipeptolides A–B (96–97) | Cyclic depsipeptide | L. majuscula | LoVo cells | 2.25 and 1.95 μg/mL | Luesch et al., 2001a |
| 20. | Ulongamides A–F (98–103) | Cyclic depsipeptide | Lyngbya sp. | KB and LoVo cells | 1 μM 5 μM | Luesch et al., 2002 |
| 21. | Obyanamide (104) | Cyclic depsipeptide | L. confervoides | KB cells | 0.58 μg/mL | Williams et al., 2002a |
| 22. | Malevamide D (105) | Linear peptide | Symploca hydnoides | P-388, A-549, HT-29, and MEL-28 | 0.7 and 0.7 nM | Horgen et al., 2002 |
| 23. | Tasiamide (106) | Linear peptide | Symploca sp. | KB and LoVo cells | 0.48 and 3.47 μg/mL | Williams et al., 2002b |
| 24. | Tasiamide B (107) | Linear peptide | KB | KB cells | 0.8 μM | Williams et al., 2003a |
| 25. | Guineamides A–F (108–113) | Cyclic depsipeptide | L. majuscula | Mouse neuroblastoma cells | 15 and 16 μM | Tan et al., 2003b |
| 26. | Homodolastatin 16 (114) | Cyclic depsipeptide | L. majuscula | Oesophageal Cervical cells | 4.3 μg/mL 1 μg/mL | Davies-Coleman et al., 2003 |
| 27. | Lyngbyastatin 3 (115) | Cyclic peptide | L. majuscula | KB and LoVo cells | 32 and 400 nM | Williams et al., 2003a |
| 28. | Ulongapeptin (116) | Cyclic depsipeptide | Lyngbya sp. | KB cells | 0.63 μM | Williams et al., 2003d |
| 29. | Tasipeptins A–B (117–118) | Depsipeptide | Symploca sp. | KB cells | 0.93 and 0.82 μM | Williams et al., 2003a |
| 30. | Jamaicamides A–C (119–121) | Lipopeptide | L. majuscula | H-460 (lung), Neuro-2a. Sodium channel blocking | 15 μM 5 μM | Williams et al., 2003d |
| 31. | Wewakpeptins A–D (122–125) | Depsipeptide | Lyngbya semiplena | NCI-H460 neuro-2a | 0.4 μM | Williams et al., 2003b |
| 32. | Trungapeptin A–C (126–128) | Cyclic depsipeptide | L. majuscula | Ichthyotoxic Brine shrimp toxicity | 6.25 ppm 10 ppm | Bunyajetpong et al., 2006 |
| 33. | Aurilides B and C (129–130) | Cyclic peptide | L. majuscula | NCI-H460 (lung), neuro-2a | 0.01 and 0.13 μM | Han et al., 2006 |
| 34. | Belamide A (131) | Tetra peptide | Symploca sp. | MCF7 (breast) HCT-116 (colon) | 0.74 μM | Simmons et al., 2006 |
| 35. | Lyngbyastatins 5–7 (132–134) | – | Lyngbya sp. | Potent Elastase Inhibitors | 3–10 nM | Taori et al., 2007 |
| 36. | Mitsoamide (135) | Linear peptide | Geitlerinema sp. | NCI-H460 (lung) | 460 nM | Andrianasolo et al., 2007 |
| 37. | Apratoxin D (136) | Cyclic depsipeptide | L. majuscule and Lyngbya sordida | H-460 (lung) | 2.6 nM | Gutiérrez et al., 2008 |
| 38. | Apratoxin E (137) | – | Lyngbya bouillonii | HT29 (colon), HeLa (cervical), | 21–72 nM | Matthew et al., 2008 |
| 39. | Dragonamide C and D (138–139) | Linear lipopeptide | Lyngbya polychroa | U2OS (osteosarcoma), HT29 (colon), IMR-32 (neuroblastoma) | 56 and 59 μM 22 and 32 μM 49 and 51 μM | Gunasekera et al., 2008 |
| 40. | Coibamide A (140) | Cyclic depsipeptide | Leptolyngbya sp. | NCI 60 cancer cell | < 23 nM | Medina et al., 2008 |
| 41. | Symplostatin 4 (141) | Linear peptide | Symploca sp. | Antimitotic to H-460 (lung) neuro-2a | 40 nM 29 nM | Taori et al., 2009 |
| 42. | Itralamides A–B (142–143) | Depsipeptide | L. majuscula | HEK293 cells | 6 ± 1 μM | Jiménez et al., 2009 |
| 43. | Desmethoxymajusculamide C (144) | Cyclic and Liner peptide | L. majuscula | HCT-116 | 20 nM | Simmons et al., 2009 |
| 44. | Hantupeptin A (145) | Cyclic depsipeptide | L. majuscula | MOLT-4 (leukemia) MCF-7 (breast) | 32 μM 4.0μM | Tripathi et al., 2008 |
| 45. | Desacetyl-Microcolin B (146) | Linear peptide | Lyngbya cf. polychroa | HT-29 andIMR-32 cells | 14 nM 14 nM | Meickle et al., 2009 |
| 46. | Palmyramide A (147) | Cyclic depsipeptide | L. majuscula | Neuro-2a and H-460 | 17.2μM 39.7μM | Taniguchi et al., 2009 |
| 47. | Bisebromoamide (148) | Linear peptide | Lyngbya sp. | Protein kinase inhibitor (HeLa S3 cells) | 04 μg/mL | Teruya et al., 2009 |
| 48. | Lyngbyabellin J (149) Lyngbyapeptin D (150) | Linear peptide | L. bouillonii | Actin-disrupting | 0.041 μM | Matthew et al., 2010 |
| 49. | Grassypeptolides A–C (151–153) | Cyclic depsipeptide | L. confervoides | HT29 cells HeLa cells | 1.22μM, 4.97μM, 76.7nM 1.01μM, 2.93μM, 44.6 nM | Kwan et al., 2010 |
| 50. | Hantupeptin B and C (154–155) | Cyclodepsipeptide | L. majuscula | MOLT-4 cells MCF-7 cells | 0.2 μM 0.5 μM | Tripathi et al., 2010 |
| 51. | Lyngbyacyclamides A–B (156–157) | Cyclic peptide | Lyngbya sp | B16 mouse melanoma | 0.7 μM | Maru et al., 2010 |
| 52. | Grassypeptolides D–E (158–159) | Cyclic depsipeptide | Leptolyngbya sp. | HeLa and neuro-2a blastoma | 335 and 192 nM 599 and 407 nM | Thornburg et al., 2011 |
| 53. | Grassypeptolides F and G (160–161) | Cyclic depsipeptide | L. majuscula | Inhibit transcription (AP-1 cell) | 5.2 and 6.0 μM | Popplewell et al., 2011 |
| 54. | Veraguamides A–H and J-L (162–172) | – | Symploca hydnoides | H-460 (lung) | 141 nM | Mevers et al., 2011; Salvador et al., 2011 |
| 55. | Malyngamide 3 (173) and Cocosamide A–B (174–175) | Cyclic peptide | L. majuscula | HT-29 cells | 48 μM, 24 μM, 11μM | Gunasekera et al., 2011 |
| 56. | Cyclodepsipeptide (176–180) | Cyclodepsipeptide | L. majuscula | HT-29 and MCF7 | – | Montaser et al., 2010 |
| 57. | Lagunamide C (181) | Cyclodepsipeptide | L. majuscula | HT-29 and MCF7 | 2.1–24.4 nM | Tripathi et al., 2011 |
| 58. | Wewakamide A (182) Guineamide G (183) | Cyclic depsipeptide | L. semiplena and L. majuscula | Neuro-2a blastoma | 2.7 μM | Nan et al., 2011 |
| 59. | Porpoisamide A–B (184–185) | Cyclic depsipeptide | Lyngbya sp. | HCT-116 (colon) cells U2OS (osteosarcoma) cells | 25, 21μM 28, 22 μM | Meickle et al., 2011 |
| 60. | Lyngbyabellin K and L (186–187), 7-epi-lyngbyabellin L (188) and Lyngbyabellin M-N (189–190) | Lipopeptide | Moorea bouillonii | HCT116 (colon) cells | 40.9 ± 3.3 nM | Choi et al., 2012 |
| 61. | Viequeamides A–D (191–194) | Cyclic depsipeptide | Rivularia sp. | H460 (lung) cells | 60 ± 10 nM | Boudreau et al., 2012 |
| 62. | Symplocin A (195) | Linear peptide | Symploca sp. | Cathepsin E inhibitor | 300 pM | Molinski et al., 2012 |
| 63. | Bouillonamide (196) | Cyclic depsipeptide | M. bouillonii | Neuron 2a cells | 6.0 μM | Tan et al., 2013 |
| 64. | Malyngamide 4 (197) | Lipopeptide | Moorea producens | HTCLs | – | Shaala et al., 2013 |
| 65. | Kurahyne B (198) | – | Okeania sp. | HeLa and HL60 | 8.1 and 9.0 μM | Okamoto et al., 2015 |
| FUNGI | ||||||
| 66. | N-Methylsansalvamide (199) | Cyclic depsipeptide | Fusarium strain CNL-619 | Tumor cell | 8.3 μM | Cueto et al., 2000 |
| 67. | Dictyonamides A–B (200–201) | Linear dodecapeptide | Fungus K063 | Kinase 4 inhibitor | 16.5 μg/mL | Komatsu et al., 2001 |
| 68. | Scytalidamides A–B (202–203) | Cyclic heptapeptide | Scytalidium sp. | HCT-116 (colon) | 7 and 11.0 μM | Tan et al., 2003a |
| 69. | Trichodermamides A–B (204–205) | Dipeptide | Trichoderma virens | HCT-116 (colon) | 0.32 μg/mL | Garo et al., 2003 |
| 70. | Rostratins A–D (206–209) | Cyclic dipeptide | Exserohilum rostratum | HCT-116 (colon) | 8.5, 1.9, 0.76 and 16.5 μg/mL | Tan et al., 2004 |
| 71. | IB-01212 (210) | Cyclic depsipeptide | Clonostachys sp. ESNA,A009 | LN-caP (prostrate), SK-BR3 (breast), HT29 (colon) and HELA (cervix) | 10-8 M | Cruz et al., 2006 |
| 72. | Zygosporamide (211) | Cyclic Penta depsipeptide | Zygosporium masonii | SF-26 (CNS) RXF 393 (renal) | 6.5 nM ≤ 5.0 nM | Oh et al., 2006 |
| 73. | Trichoderide A (212) | – | Trichoderma reesei | A375-S2 melanoma | 18.5 mg/mL | Sun et al., 2006 |
| 74. | Spicellamide A–B (213–214) | Cyclo hexadepsipeptide | Spicellum roseum | Neuron 2a cells | 30 μg/mL and 6.2 μg/mL | (Kralj et al., 2007 |
| 75. | 1962A and 1962B (215–216) | Cyclic depsipeptide | Strain No. 1962 | MCF-7 (breast) | 100 μg/mL | Huang et al., 2007) |
| 76. | Microsporins A–B (217–218) | Cyclic tetrapeptide | Microsporum cf. gypseum | HCT-116, Potent inhibitors of HDAC | 0.6 μg/mL and 8.5 μg/mL | Gu et al., 2007 |
| 77. | Efrapeptin J (219) | Penta decapeptide | Tolypocladium sp. | HT1080 | – | Hayakawa et al., 2008 |
| 78. | Cotteslosin A–B (220–221) | Cyclo pentapeptide | Aspergillus versicolor | MM418c5 (melanoma), DU145 (prostate), T47D (breast) | 66 μg/mL 94 μg/mL 90 μg/mL | Fremlin et al., 2009 |
| 79. | Versicotide A–B (222–223) | Cyclo pentapeptide | A. versicolor | Anti-tumor | – | Zhou et al., 2011 |
| 80. | Fellutamide F (224) | Lipopeptide | A. versicolor | SK-MEL-2 (skin) XF498 (CNS) HCT15 (Colon) | 0.67 μM 0.14 μM 0.13 μM | Lee et al., 2011 |
| 81. | Cordyheptapeptides C–E (225–227) | Cyclo heptapeptide | Acremonium persicinum | SF-268, MCF-7, and NCI-H460 | 2.5–12.1 μM | Chen et al., 2012 |
| 82. | Pullularin E and F (228–229) | – | Bionectria ochroleuca | L5178Y (lymphoma) | 0.1 and 6.7 μg/mL | Ebrahim et al., 2012 |
| 83. | Clavatustides A–C (230–232) | Cyclodepsipeptide | Aspergillus clavatus | Hepatocellular Carcinoma Cycle Inhibitory | – | Jiang et al., 2013; Ye et al., 2014 |
| 84. | Asperterrestide A (233) | Cyclic tetrapeptide | Aspergillus terreus | U937 (carcinoma) and MOLT4 cell | 6.4 and 6.2 μM | He et al., 2013 |
| 85. | Similanamide (234) | Cyclohexapeptide | Aspergillus similanensis | MCF-7 (breast), NCI-H460 (lung) and A373 (melanoma) | 125 ± 0 117.50 ± 3.55 115 ± 7.07 | Prompanya et al., 2015 |